Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial

BACKGROUND: Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by initial estimated glomerular filtration rate (eGFR). METHODS: CREDENCE randomly assigned 4401 participants with an eGFR of 30 to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Am Soc Nephrol
Hauptverfasser: Jardine, Meg J., Zhou, Zien, Mahaffey, Kenneth W., Oshima, Megumi, Agarwal, Rajiv, Bakris, George, Bajaj, Harpreet S., Bull, Scott, Cannon, Christopher P., Charytan, David M., de Zeeuw, Dick, Di Tanna, Gian Luca, Greene, Tom, Heerspink, Hiddo J.L., Levin, Adeera, Neal, Bruce, Pollock, Carol, Qiu, Rose, Sun, Tao, Wheeler, David C., Zhang, Hong, Zinman, Bernard, Rosenthal, Norman, Perkovic, Vlado
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Nephrology 2020
Schlagworte:
Clinical Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7217416/
https://ncbi.nlm.nih.gov/pubmed/32354987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2019111168
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge